At Reviva we are focused on developing a drug that targets both the serotonin and dopamine receptor signaling systems to more effectively treat schizophrenia and its comorbid symptoms.” ...

“The end game is trying to relate [dopamine signaling] back to schizophrenia and other disorders with working memory impairment,” study coauthor Joshua Roffman of MGH and Harvard University told The ...

The U.S. Food and Drug Administration approved a new schizophrenia treatment ... first to target cholinergic receptors ...

The advantage of atypical agents for alleviating impaired cognitive function in schizophrenia may be related to actions on 5-HT receptors. 5-HT 1A receptors are one of the most promising targets ...

OPC-4392 was shown to be effective against negative symptoms and showed no propensity to induce extrapyramidal symptoms in individuals with schizophrenia ... of the dopamine receptors in several ...

This is the first-ever drug approved for schizophrenia that does not target the D2 dopamine receptor in brain cells. Xanomeline works by targeting two specific receptors in brain cells ...

The drug – a selective muscarinic M4 receptor positive allosteric modulator (PAM) – is designed to have limited effect on dopamine neurotransmission ... Scale (PANSS) of schizophrenia symptoms ...

Caplyta is a prescription drug used to treat schizophrenia and bipolar disorder. Learn how long it takes the drug to work and how long it stays in your system.

For around 70 years, the treatment of schizophrenia has relied almost entirely on drugs that block dopamine D2 receptors, but KarXT is one of a clutch of new therapies emerging from the pharma ...

Cobenfy, the main asset acquired through Bristol Myers’ $14 billion purchase of Karuna, had $10 million in sales in the ...

Her seminal study on dopamine release in chronic cannabis users, published in Biological Psychiatry and cited over 152 times, has become a cornerstone in addiction and schizophrenia research.

Thus far, drugs for schizophrenia have worked by blocking dopamine – a neurotransmitter ... Cobenfy, however, targets a different family of receptors in the brain, known as muscarinic receptors.